Brendan A. Creemer

This study evaluates AlphaFold's ability to model nanobody-peptide interactions, finding moderate success in some cases but limitations when translating to complex contexts.

The paper describes a method to create highly biased agonists for GPCRs by tethering a peptide ligand to a nanobody, achieving pathway selectivity without altering the core ligand structure.